Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory
non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular
pathologic NHL subtype(s).